Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Little Pre- and Postmarket Testing for Most Recalled CV Devices

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

May 09, 2023

FDA Approves Empagliflozin for Treatment of HFpEF

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

May 06, 2020

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.